Equities researchers at StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.
Oragenics Stock Performance
Shares of NYSE OGEN opened at $0.31 on Friday. Oragenics has a 52-week low of $0.29 and a 52-week high of $7.74. The stock has a market cap of $1.41 million, a P/E ratio of -0.04 and a beta of 0.45. The firm has a 50 day moving average price of $0.58 and a 200 day moving average price of $1.11.
Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Oragenics
About Oragenics
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- What is a Death Cross in Stocks?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Bank Stocks – Best Bank Stocks to Invest In
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- High Flyers: 3 Natural Gas Stocks for March 2022
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.